Investments and investor services
FTSE 100: The good, the BATS and the Ocado in 2018
For Ocado, it was a case of "eat my shorts" as short sellers got burnt while for BATS, not enough cigarettes got burnt as e-cigarettes rose in popularity
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 35 of 55
Hat-trick for AstraZeneca as its cancer and anaemia drugs come up trumps in three late-stage trials
Lynparza improved response rates in a subset of ovarian cancer patients, while Roxadustat boosted haemoglobin count in people with anaemia
GlaxoSmithKline shares drift lower as Morgan Stanley reinitiates coverage with ‘underweight’ stance
The US investment bank set a price target of 1,460p on the FTSE 100-listed firm, with Glaxo's shares trading at 1,476.20p late morning, down 0.4% on Thursday’s closing price
Sterling slump: Who’s benefitting?
On Monday, fresh Brexit volatility pushed the pound to a yearly low against the dollar but despite the turmoil, some firms are profiting handsomely
AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial
The drug failed to prolong the lives of patients with advanced head and neck cancers when it was used alone or in combination with another treatment, in comparison to standard chemo
Barclays downgrades GSK; warns of “significant EPS dilution” from Tesaro acquisition
Barclays reckons the GSK valuation remains appealing, but is waiting until 2019 before piling back in, as it thinks the shares might drift a little lower yet
AstraZeneca in cancer drug setback
The phase III trial involved patients with very late stage lung cancer where the disease had spread to other organs - in other words, the group was hard to treat
Investments and investor services
FTSE 100 closes Friday in the red after tumultuous week for UK politics
The UK's premier share index lost around 24 points at 7,013 on the day - and was down 1.29% on the week.
AstraZeneca sells off US rights to children’s lung disease treatment for up to US$2bn
Over the past couple of weeks, the FTSE 100 drugs giant has sold off the rights to three asthma and hay fever treatments, one heartburn medicine, an arthritis drug and now a lung disease treatment
AstraZeneca serves up a double dose of good news
It said the US regulator had granted a priority review for its new cancer treatment and told investors a phase III trial of its diabetes medication delivered impressive results
Growing opportunities in respiratory space could accelerate Circassia’s path to profitability, says analyst
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
AstraZeneca confirms full-year guidance; CEO says results mark an important milestone
Total revenues were still stuck in reverse gear, but the underlying picture, measured by product sales, was healthier with the figure up 8% to US$5.27bn
Investments and investor services
FTSE 100 closes higher ahead of Federal Reserve meeting
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Investments and investor services
J Sainsbury and retailers to be among highlights amid busy Thursday schedule
Sainsbury, Superdry and Burberry are among the names in the diary for Thursday.
AstraZeneca sells off three more non-core drugs for US$370mln
The UK drugs giant has been selling off lots of ‘non-core’ drugs in recent years to help keep money flowing in while it spends millions developing its pipeline
N4 Pharma surges as MedImmune agrees to extend collaboration deal
The two parties had been working together as part of a project funded by the UK government and they have agreed to continue their research
Archive
Trump mid-term test and US rate decision to give week ahead a Trans-Atlantic twist
Aside from the US elections and Fed policy meeting, updates from UK blue-chip retailers J Sainsbury, Wm Morrison Supermarkets and Marks & Spencer should draw the most attention in the coming week
Concepta readies for imminent UK launch of myLotus in first milestone of European strategy
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
AstraZeneca sells rights to two of its ‘non-core’ drugs for almost US$1bn
Both Nexium, a treatment for heartburn, and Vimovo, used to treat arthritis, fall outside of AstraZeneca’s three main focus areas of cancer, cardiovascular and renal and respiratory
AstraZeneca reveals trial of Lynparza drug reduces risk of ovarian cancer worsening
Deutsche Bank said the successful trial of Lynparza further increases its ‘buy’ conviction and raised its target price to 6,500p from 6,400p